[永笙生技股份有限公司] Q1 2026 EPS -0.19 NTD
Key facts
- [永笙生技股份有限公司] Q1 2026 EPS -0.19 NTD
- 永笙生技股份有限公司 reported a Q1 2026 EPS of -0.19 NTD, with operating revenue at 88 million NTD.
- Source: PR Times
- Date: March 1, 2026
Direct answer
永笙生技股份有限公司 reported a Q1 2026 EPS of -0.19 NTD, with operating revenue at 88 million NTD.
- Citation
- [永笙生技股份有限公司] Q1 2026 EPS -0.19 NTD (March 1, 2026), PR Times
- Source
- PR Times
- Date
- March 1, 2026
永笙生技股份有限公司 reported a Q1 2026 EPS of -0.19 NTD, with operating revenue at 88 million NTD.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: May 16, 2026 at 08:00 (1823h 0m after Published)
- 🤖 AI Analyzed: May 16, 2026 at 09:42 (1h 42m after Collected)
Company Code: 4178
Company Name: 永笙生技股份有限公司
Industry: Biotech and Medical
Year/Quarter: 2026 Q1
Basic EPS: -0.19 NTD
Operating Revenue: 88 million NTD
Net Income after Tax: -36 million NTD
Company Name: 永笙生技股份有限公司
Industry: Biotech and Medical
Year/Quarter: 2026 Q1
Basic EPS: -0.19 NTD
Operating Revenue: 88 million NTD
Net Income after Tax: -36 million NTD
FAQ
What are the key facts in this article?
永笙生技股份有限公司 reported a Q1 2026 EPS of -0.19 NTD, with operating revenue at 88 million NTD.
What is the direct answer?
永笙生技股份有限公司 reported a Q1 2026 EPS of -0.19 NTD, with operating revenue at 88 million NTD.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-4178-2026Q1 | March 1, 2026